Genmab A/S (OTCMKTS:GNMSF) Sets New 52-Week High - Time to Buy?

Key Points

• Genmab A/S shares reached a new 52-week high at $280.00, a significant increase from the previous close of $277.60.
• The company reported a robust quarterly earnings result with $5.42 earnings per share (EPS), exceeding the consensus estimate by $1.43.
• Genmab has a market capitalization of $18.78 billion and a return on equity of 21.03%, reflecting its strong financial performance in the biotechnology sector.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $280.00 and last traded at $280.00, with a volume of 415 shares changing hands. The stock had previously closed at $277.60.

Genmab A/S Trading Up 2.4%

The business has a fifty day moving average price of $229.39 and a two-hundred day moving average price of $213.59. The company has a market cap of $18.78 billion, a price-to-earnings ratio of 14.27 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.99 by $1.43. The business had revenue of $925.00 million for the quarter, compared to analyst estimates of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.